Anti-Hypertensive Drugs - Portugal

Portugal

In Portugal, the revenue in the Anti-Hypertensive Drugs market is estimated to reach US$45.83m in 2024.
It is projected to exhibit an annual growth rate of 0.17% (CAGR 2024-2029), leading to a market volume of US$46.22m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$12,290.00m in 2024.
In Portugal, there has been a growing demand for locally-produced anti-hypertensive drugs due to increasing awareness of the importance of hypertension management.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Portugal has been experiencing steady growth in recent years.

Customer preferences: Portuguese consumers tend to favor pharmaceutical products from established brands with a proven track record of efficacy and safety. They also tend to prefer drugs that are easily accessible and affordable. In addition, there is a growing trend towards natural and alternative therapies, which may impact the market for Anti-Hypertensive Drugs.

Trends in the market: The Anti-Hypertensive Drugs market in Portugal is primarily driven by the aging population and the high prevalence of hypertension in the country. The market is also influenced by the increasing availability of generic drugs, which are often more affordable than brand-name products. Another trend in the market is the development of new drugs and treatment options, which may offer improved efficacy and fewer side effects.

Local special circumstances: The Portuguese healthcare system is largely publicly funded, which means that the government plays a significant role in regulating the market for pharmaceutical products. In addition, there is a growing focus on preventative healthcare and lifestyle interventions, which may impact the demand for Anti-Hypertensive Drugs.

Underlying macroeconomic factors: The Portuguese economy has been recovering from the financial crisis of the late 2000s, which has led to increased consumer confidence and spending. However, the country still faces significant economic challenges, including high levels of public debt and a relatively low GDP per capita. These factors may impact the affordability and accessibility of Anti-Hypertensive Drugs for Portuguese consumers.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.